Engineered immune cells take on Hard-to-Treat prostate cancer
NCT ID NCT07298239
First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 19 times
Summary
This early-stage study tests a new treatment for men with metastatic castration-resistant prostate cancer, a form that no longer responds to standard hormone therapy. The treatment uses specially engineered natural killer (NK) cells from healthy donors to target and kill cancer cells. The main goal is to check safety and see if the therapy can shrink tumors or lower PSA levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, 不限, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.